



July 18, 2023

Good morning,

We are writing to share the exciting news that, earlier today, Neurogene Inc. and Neoleukin Therapeutics, Inc., announced an agreement to merge. The merger will create a Nasdaq-listed biotech company focused on advancing Neurogene's differentiated portfolio of genetic medicines for complex neurological diseases. The full press release announcing today's news can be found at: <https://www.neurogene.com/press-releases/neurogene-and-neoleukin-announce-definitive-merger-agreement/>

This merger and associated financing will help fund our future growth and development, enabling us to advance our mission of bringing life-changing genetic medicines to patients and families impacted by devastating neurological diseases.

This change will not impact our day-to-day activities or interactions with the patient community. The existing Neurogene team will remain dedicated to our work with the same sense of purpose and unwavering commitment to patients and families.

The merger is expected to be completed in the fourth quarter of 2023.

We value our relationship with the patient community and will provide updates as they are available.

Please do not hesitate to reach out to us with any questions.

Neurogene contact information:

- By phone: +1-877-237-5020
- Patients and families can reach us at: patientinfo@neurogene.com
- Healthcare providers can reach us at: medicalinfo@neurogene.com
- Our website is: www.neurogene.com

We are on social media at the following channels:

- Neurogene Inc. Facebook page: <https://www.facebook.com/NeurogeneInc/>
- Neurogene Inc. Twitter handle: <https://twitter.com/NeurogeneInc/>
- Neurogene Inc. LinkedIn profile: <https://www.linkedin.com/company/NeurogeneInc>

Sincerely,

Kimberly Trant
Executive Director, Patient Advocacy and Engagement